Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 11:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Blood Component Transfusion Clear all
Recruiting Phase 1Phase 2 Interventional

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

NCT03653338
View directory record Official record
Conditions
Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia
Interventions
CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea, Rituximab, Alemtuzumab, Fludarabine, Thiotepa
Biological · Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
5 Years to 40 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 11, 2026, 11:21 PM EDT
Active, not recruiting No phase listed Observational

Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

NCT02633943
View directory record Official record
Conditions
Transfusion-dependent Beta-Thalassemia
Interventions
Safety and efficacy assessments
Other
Lead sponsor
Genetix Biotherapeutics Inc.
Industry
Eligibility
0 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2035
U.S. locations
6
States / cities
Oakland, California • Chicago, Illinois • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 11, 2026, 11:21 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Fetoscopic Selective Laser Photocoagulation in Twin-Twin Transfusion Syndrome

NCT00345852
View directory record Official record
Conditions
Twin to Twin Transfusion Syndrome
Interventions
Fetoscopic Selective Laser Photocoagulation
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
12
States / cities
San Francisco, California • Evanston, Illinois • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2007 · Synced Sep 11, 2026, 11:21 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants

NCT01203514
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Anemia, Neonatal
Interventions
Erythropoietin, Sham Comparator
Drug · Other
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
24 Hours to 96 Days
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
9
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Sep 11, 2026, 11:21 PM EDT
Terminated Early Phase 1 Interventional

A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)

NCT05284032
View directory record Official record
Conditions
Platelet Refractoriness, Hematologic Malignancy
Interventions
isatuximab 10 mg/kg
Drug
Lead sponsor
Firas El Chaer, MD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 11, 2026, 11:21 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Allo HSCT for High Risk Hemoglobinopathies

NCT06872333
View directory record Official record
Conditions
Graft Failure, Sickle Cell Disease, Hemoglobinopathies
Interventions
Alemtuzumab, Total Body Irradiation, Cell Infusion, Thymoglobulin, Fludarabine, Busulfan, Cyclophosphamide, Sirolimus, Tacrolimus, Mycophenolate Mofetil, Plerixafor (mozobil)
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2032
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 11, 2026, 11:21 PM EDT
Terminated Phase 2 Interventional Results available

RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery

NCT01283321
View directory record Official record
Conditions
Heart Valve Disease, Coronary Artery Disease
Interventions
Human fibrinogen concentrate, apheresis platelets
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Sep 11, 2026, 11:21 PM EDT
Completed Not applicable Interventional

High Yield Intraoperative, Autologous Platelet Apheresis

NCT01819246
View directory record Official record
Conditions
Allogenic Transfusion of Platelets During Cardiac Surgery
Interventions
Aphersis Treatment Arm, Control Arm
Procedure · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Sep 11, 2026, 11:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Point-of-Care RBC Washing to Prevent Transfusion-Related Pulmonary Complications

NCT02094118
View directory record Official record
Conditions
Blood Transfusion Complications
Interventions
Point-of-care washed red blood cell transfusion., Standard of care red blood cell transfusion.
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 11, 2026, 11:21 PM EDT
Terminated Phase 2 Interventional

Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

NCT01422486
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
ezatiostat hydrochloride (Telintra®)
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Maywood, Illinois • Springfield, Illinois • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Sep 11, 2026, 11:21 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Age of Blood in Sickle Cell Transfusion

NCT03704922
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Transfusion
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 11, 2026, 11:21 PM EDT
Completed No phase listed Observational

PICU Transfusion Study: Harmful Effects of Red Blood Cell Transfusions

NCT02087553
View directory record Official record
Conditions
Iron, Abnormal Blood Level
Interventions
Transfusion of red blood cells, Infusion of albumin/saline
Biological
Lead sponsor
Columbia University
Other
Eligibility
Up to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 11, 2026, 11:21 PM EDT
Completed Phase 3 Interventional Results available

Red Cell Storage Duration Study

NCT00991341
View directory record Official record
Conditions
Cardiac Surgery, Erythrocyte Transfusion
Interventions
Red blood cell units stored <= 10 days, Red blood cell units stored >= 21 days
Biological
Lead sponsor
Carelon Research
Other
Eligibility
12 Years and older
Enrollment
1,481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
33
States / cities
Gainesville, Florida • Atlanta, Georgia • Fort Wayne, Indiana + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Sep 11, 2026, 11:21 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Reversal of Aspirin Antiplatelet Therapy With Cold Stored Platelets

NCT05111028
View directory record Official record
Conditions
Reversal of Platelet Aggregation Inhibitors
Interventions
Autologous Room Temperature stored Platelet transfusion, Autologous Cold Stored Platelet transfusion
Biological
Lead sponsor
Bloodworks
Other
Eligibility
18 Years to 59 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 11, 2026, 11:21 PM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

NCT01566695
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Oral Azacitidine, Placebo, Best Supportiv Care (BSC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
40
States / cities
Berkeley, California • Beverly Hills, California • Duarte, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 11, 2026, 11:21 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT02598661
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Imetelstat Sodium, Placebo
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Bakersfield, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 11, 2026, 11:21 PM EDT
Completed Phase 1 Interventional

Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension

NCT00023296
View directory record Official record
Conditions
Sickle Cell Anemia, Pulmonary Hypertension
Interventions
Nitric Oxide, INO Pulse - NO Delivery System
Drug · Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 11, 2026, 11:21 PM EDT
Completed Early Phase 1 Interventional Results available

RHD Genotype Matched Red Cells for Anti-D

NCT04156906
View directory record Official record
Conditions
Sickle Cell Disease, Anti-D Antibodies
Interventions
D+ RH genotype matched red cell units for transfusion
Biological
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 11, 2026, 11:21 PM EDT
Completed Not applicable Interventional

Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery

NCT01220011
View directory record Official record
Conditions
Blood and Blood Disorders, Anemia, Neonatal, Hematologic Disease, Infant, Newborn, Diseases
Interventions
Fetoscopic laser surgery
Procedure
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Other
Eligibility
18 Years and older · Female only
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
8
States / cities
Aurora, Colorado • Baltimore, Maryland • Cincinnati, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 11, 2026, 11:21 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia

NCT01464164
View directory record Official record
Conditions
Diamond Blackfan Anemia
Interventions
Sotatercept, Sotatercept with prednisone boost
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Sep 11, 2026, 11:21 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets

NCT00074763
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Platelet Transfusion
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Sep 11, 2026, 11:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Transfusion Trigger After Operations in High Cardiac Risk Patients

NCT03229941
View directory record Official record
Conditions
Myocardial Infarction, Coronary Revascularization, Acute Renal Failure
Interventions
Blood Transfusion
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,424 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
16
States / cities
Little Rock, Arkansas • Loma Linda, California • Long Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 11, 2026, 11:21 PM EDT
Completed No phase listed Observational Results available

The Effect of Hypotensive Anesthesia on Hemoglobin Levels During Total Knee Arthroplasty

NCT05340751
View directory record Official record
Conditions
Anesthesia
Interventions
Blood drawn
Diagnostic Test
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
40 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 11, 2026, 11:21 PM EDT
Completed Phase 3 Interventional

Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement

NCT00668031
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Trasylol (Aprotinin, BAYA0128), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
27
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Sep 11, 2026, 11:21 PM EDT